Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax

This publication has 15 references indexed in Scilit:

• Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research
  Vaccine, 2008
• Vivax Malaria: Neglected and Not Benign
  The American Journal of Tropical Medicine and Hygiene, 2007
• Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
  The Lancet, 2007
• Neglect of Plasmodium vivax malaria
  Trends in Parasitology, 2007
• An update on the search for a Plasmodium vivax vaccine
  Trends in Parasitology, 2007
• Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
  The Lancet, 2005
• Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
  The Lancet, 2004
• Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria
  The Journal of Infectious Diseases, 2001
• A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria
  New England Journal of Medicine, 1997
• Circumsporozoite proteins of malaria parasites
  Cell, 1985